$CRDF
Cardiff Oncology, Inc. Stock $crdf

$crdf Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000162828022021044 Filed on August 04, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$93.00K	$91.00K	$74.00K
YoY Change	8.14%	33.82%	2.78%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.077M	$3.086M	$3.940M
YoY Change	5.02%	8.74%	76.29%
% of Gross Profit
Research & Development	$6.009M	$7.448M	$7.208M
YoY Change	44.66%	80.82%	119.82%
% of Gross Profit
Depreciation & Amortization	$81.00K	$38.00K	$31.00K
YoY Change	-26.36%	-64.81%	-73.95%
% of Gross Profit
Operating Expenses	$9.086M	$10.53M	$11.15M
YoY Change	28.26%	51.42%	102.18%
Operating Profit	-$8.993M	-$10.44M	-$11.07M
YoY Change	28.51%	51.59%	103.49%
Interest Expense	$458.0K	$253.0K	$130.0K
YoY Change	458.54%	91.67%	-50.0%
% of Operating Profit
Other Income/Expense, Net	$422.0K	$0.00	$81.00K
YoY Change	13966.67%	-100.0%	-69.2%
Pretax Income	-$8.571M	-$10.44M	-$10.99M
YoY Change	23.98%	54.55%	112.22%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$8.571M	-$10.44M	-$10.99M
YoY Change	23.98%	54.55%	112.26%
Net Earnings / Revenue	-9216.13%	-11475.82%	-14855.41%
Basic Earnings Per Share	-$0.20	-$0.24	-$0.25
Diluted Earnings Per Share	-$0.20	-$0.24	-$0.25
COMMON SHARES
Basic Shares Outstanding	43.33M shares	43.31M shares	43.23M shares
Diluted Shares Outstanding	43.33M shares	43.31M shares	43.23M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$107.2M	$115.7M	$114.5M
YoY Change	-20.02%	-17.4%	-8.87%
Cash & Equivalents	$18.72M	$20.97M	$20.05M
Short-Term Investments	$88.50M	$94.72M	$94.41M
Other Short-Term Assets	$4.802M	$4.857M	$5.997M
YoY Change	44.33%	93.35%	122.11%
Inventory
Prepaid Expenses	$4.802M	$4.857M	$5.997M
Receivables	$650.0K	$551.0K	$447.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$119.8M	$127.4M	$135.8M
YoY Change	-13.08%	-10.82%	5.63%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.304M	$1.138M	$550.0K
YoY Change	240.47%	169.67%	9.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$184.0K	$185.0K	$188.0K
YoY Change	28.67%	-29.66%	-21.01%
Total Long-Term Assets	$3.876M	$3.847M	$3.398M
YoY Change	9.4%	345.77%	238.78%
TOTAL ASSETS
Total Short-Term Assets	$119.8M	$127.4M	$135.8M
Total Long-Term Assets	$3.876M	$3.847M	$3.398M
Total Assets	$123.6M	$131.3M	$139.2M
YoY Change	-12.51%	-8.68%	7.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.425M	$1.522M	$1.261M
YoY Change	259.85%	180.29%	57.04%
Accrued Expenses	$6.138M	$6.279M	$4.738M
YoY Change	53.07%	74.81%	57.99%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.245M	$8.481M	$6.664M
YoY Change	63.53%	85.22%	48.78%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.174M	$2.306M	$2.438M
YoY Change	7146.67%	977.57%	1176.44%
Total Long-Term Liabilities	$2.174M	$2.306M	$2.438M
YoY Change	7146.67%	977.57%	1176.44%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.245M	$8.481M	$6.664M
Total Long-Term Liabilities	$2.174M	$2.306M	$2.438M
Total Liabilities	$10.42M	$10.79M	$9.102M
YoY Change	34.13%	123.98%	91.38%
SHAREHOLDERS EQUITY
Retained Earnings	-$289.8M	-$281.3M	-$270.8M
YoY Change	15.77%	15.53%	14.42%
Common Stock	$4.000K	$4.000K	$4.000K
YoY Change	0.0%	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$113.2M	$120.5M	$130.1M
YoY Change
Total Liabilities & Shareholders Equity	$123.6M	$131.3M	$139.2M
YoY Change	-12.51%	-8.68%	7.43%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$8.571M	-$10.44M	-$10.99M
YoY Change	23.98%	54.55%	112.26%
Depreciation, Depletion And Amortization	$81.00K	$38.00K	$31.00K
YoY Change	-26.36%	-64.81%	-73.95%
Cash From Operating Activities	-$7.486M	-$6.695M	-$10.25M
YoY Change	36.98%	55.52%	74.18%
INVESTING ACTIVITIES
Capital Expenditures	-$448.0K	-$312.0K	$171.0K
YoY Change	357.14%
Acquisitions
YoY Change
Other Investing Activities	$5.611M	$7.920M	$18.53M
YoY Change	-31.13%	-141.68%	-116.59%
Cash From Investing Activities	$5.163M	$7.608M	$18.36M
YoY Change	-35.86%	-140.04%	-116.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	75.00K	0.000	$0.00
YoY Change		-100.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-7.486M	-6.695M	-$10.25M
Cash From Investing Activities	5.163M	7.608M	$18.36M
Cash From Financing Activities	75.00K	0.000	$0.00
Net Change In Cash	-2.248M	913.0K	$8.109M
YoY Change	-187.0%	-122.38%	-106.97%
FREE CASH FLOW
Cash From Operating Activities	-$7.486M	-$6.695M	-$10.25M
Capital Expenditures	-$448.0K	-$312.0K	$171.0K
Free Cash Flow	-$7.038M	-$6.383M	-$10.42M
YoY Change	31.13%		77.09%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001213037
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-35558
	dei	Entity Registrant Name EntityRegistrantName	CARDIFF ONCOLOGY, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-2004382
	dei	Entity Address Address Line1 EntityAddressAddressLine1	11055 Flintkote Avenue
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
	dei	City Area Code CityAreaCode	858
	dei	Local Phone Number LocalPhoneNumber	952-7570
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	CRDF
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	43334919	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20965000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11943000	usd
CY2022Q2	us-gaap	Short Term Investments ShortTermInvestments	101041000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	128878000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	551000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	535000	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4857000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4771000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	127414000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	146127000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1138000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	382000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2524000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2796000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	185000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	239000	usd
CY2022Q2	us-gaap	Assets Assets	131261000	usd
CY2021Q4	us-gaap	Assets Assets	149544000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1522000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1439000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6279000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4527000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	670000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	551000	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	10000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	42000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	8481000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6559000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2306000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2568000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	10787000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	9127000	usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	1000	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43306000	shares
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	402710000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	400503000	usd
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43306000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41964000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41964000	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2022Q2	crdf	Service Receivable ServiceReceivable	0	usd
CY2021Q4	crdf	Service Receivable ServiceReceivable	139000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-982000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-142000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-281258000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-259810000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	120474000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	140417000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	131261000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	149544000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	91000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	68000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	165000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	140000	usd
CY2022Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	7448000	usd
CY2021Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	4119000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	14656000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	7398000	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3086000	usd
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2838000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7026000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5073000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	10534000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	6957000	usd
	us-gaap	Operating Expenses OperatingExpenses	21682000	usd
	us-gaap	Operating Expenses OperatingExpenses	12471000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-10443000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6889000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21517000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12331000	usd
CY2022Q2	us-gaap	Interest Income Operating InterestIncomeOperating	253000	usd
CY2021Q2	us-gaap	Interest Income Operating InterestIncomeOperating	71000	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	383000	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	115000	usd
CY2022Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	usd
CY2021Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	61000	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	268000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-253000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-302000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	12000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	0	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	132000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	81000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	395000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-10443000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-6757000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21436000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11936000	usd
CY2022Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6000	usd
CY2021Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	12000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	12000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10449000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6763000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21448000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11948000	usd
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.50
	us-gaap	Net Income Loss NetIncomeLoss	-21436000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.50
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43306000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43306000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38761000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38761000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43269000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43269000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37967000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37967000	shares
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-10443000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-6757000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11946000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11936000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-234000	usd
CY2022Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6000	usd
CY2021Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	12000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	57000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-840000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-10000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10677000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6700000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22276000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	12000	usd
CY2022Q2	crdf	Comprehensive Income Loss Available To Common Stockholders Basic ComprehensiveIncomeLossAvailableToCommonStockholdersBasic	-10683000	usd
CY2021Q2	crdf	Comprehensive Income Loss Available To Common Stockholders Basic ComprehensiveIncomeLossAvailableToCommonStockholdersBasic	-6706000	usd
	crdf	Comprehensive Income Loss Available To Common Stockholders Basic ComprehensiveIncomeLossAvailableToCommonStockholdersBasic	-22288000	usd
	crdf	Comprehensive Income Loss Available To Common Stockholders Basic ComprehensiveIncomeLossAvailableToCommonStockholdersBasic	-11958000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	140417000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1152000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-606000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	-1000	usd
CY2022Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6000	usd
CY2022Q1	crdf	Release Of Clinical Trial Funding Commitment ReleaseOfClinicalTrialFundingCommitment	139000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-10993000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	130102000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1055000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-234000	usd
CY2022Q2	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-10443000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	120474000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	128158000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	268000	usd
CY2021Q1	crdf	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1263000	usd
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-67000	usd
CY2021Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6000	usd
CY2021Q1	crdf	Release Of Clinical Trial Funding Commitment ReleaseOfClinicalTrialFundingCommitment	380000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-5179000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	124817000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1036000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	19225000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	57000	usd
CY2021Q2	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6000	usd
CY2021Q2	crdf	Release Of Clinical Trial Funding Commitment ReleaseOfClinicalTrialFundingCommitment	546000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-6757000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	138918000	usd
CY2022Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	800000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21436000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11936000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-1000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	69000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	228000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2207000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1304000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-557000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-698000	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	268000	usd
	crdf	Release Of Clinical Trial Funding Commitment For Services Received ReleaseOfClinicalTrialFundingCommitmentForServicesReceived	139000	usd
	crdf	Release Of Clinical Trial Funding Commitment For Services Received ReleaseOfClinicalTrialFundingCommitmentForServicesReceived	926000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-54000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-141000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	16000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-12000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-18000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-68000	usd
	crdf	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-272000	usd
	crdf	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-165000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1367000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1121000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-143000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-461000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-32000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	58000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16944000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10185000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	483000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
	us-gaap	Proceeds From Insurance Settlement Investing Activities ProceedsFromInsuranceSettlementInvestingActivities	71000	usd
	us-gaap	Proceeds From Insurance Settlement Investing Activities ProceedsFromInsuranceSettlementInvestingActivities	0	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	48801000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	5510000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	57309000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	141948000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	122000000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	34886000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	5735000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	25966000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-130703000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	776000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	19225000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1263000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20488000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9022000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-120400000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11943000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130981000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20965000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10581000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	456000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	27000	usd
	crdf	Capital Expenditures Included With Insurance Proceeds Receivable CapitalExpendituresIncludedWithInsuranceProceedsReceivable	43000	usd
	crdf	Capital Expenditures Included With Insurance Proceeds Receivable CapitalExpendituresIncludedWithInsuranceProceedsReceivable	0	usd
	crdf	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	12000	usd
	crdf	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	12000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10964481	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10142486	shares
CY2022Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	95637000	usd
CY2022Q2	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent	1000	usd
CY2022Q2	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent	915000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	94723000	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	6386000	usd
CY2022Q2	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent	0	usd
CY2022Q2	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent	68000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	6318000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	102023000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	983000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	101041000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	95643000	usd
CY2021Q4	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent	6000	usd
CY2021Q4	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent	65000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	95584000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	33377000	usd
CY2021Q4	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent	1000	usd
CY2021Q4	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent	84000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	33294000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	129020000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	149000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	128878000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4613000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3823000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3475000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3441000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1138000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	382000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1304000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1435000	usd
CY2022Q2	crdf	Accrued Preferred Stock Dividend AccruedPreferredStockDividend	426000	usd
CY2021Q4	crdf	Accrued Preferred Stock Dividend AccruedPreferredStockDividend	414000	usd
CY2022Q2	crdf	Accrued Clinical Trial AccruedClinicalTrial	1780000	usd
CY2021Q4	crdf	Accrued Clinical Trial AccruedClinicalTrial	1639000	usd
CY2022Q2	crdf	Accrued Research Agreements AccruedResearchAgreements	1697000	usd
CY2021Q4	crdf	Accrued Research Agreements AccruedResearchAgreements	726000	usd
CY2022Q2	crdf	Accrued Director Fees AccruedDirectorFees	122000	usd
CY2021Q4	crdf	Accrued Director Fees AccruedDirectorFees	141000	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	28000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	63000	usd
CY2022Q2	crdf	Patent License And Other Fees Payable PatentLicenseAndOtherFeesPayable	40000	usd
CY2021Q4	crdf	Patent License And Other Fees Payable PatentLicenseAndOtherFeesPayable	43000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	882000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	66000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6279000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4527000	usd
	crdf	Lessee Operating Lease Area Of Lease LesseeOperatingLeaseAreaOfLease	12300	sqft
	crdf	Lessee Operating Lease Monthly Rent Payment LesseeOperatingLeaseMonthlyRentPayment	60000	usd
	crdf	Lessee Operating Lease Annual Rent Increase Percentage LesseeOperatingLeaseAnnualRentIncreasePercentage	0.03
	crdf	Lessor Number Of Subleases LessorNumberOfSubleases	3	lease
	crdf	Lessor Area Of Sublease LessorAreaOfSublease	16600	sqft
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	190000	usd
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	92000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	381000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	187000	usd
CY2022Q2	us-gaap	Sublease Income SubleaseIncome	0	usd
CY2021Q2	us-gaap	Sublease Income SubleaseIncome	101000	usd
	us-gaap	Sublease Income SubleaseIncome	0	usd
	us-gaap	Sublease Income SubleaseIncome	202000	usd
CY2022Q2	us-gaap	Lease Cost LeaseCost	190000	usd
CY2021Q2	us-gaap	Lease Cost LeaseCost	-9000	usd
	us-gaap	Lease Cost LeaseCost	381000	usd
	us-gaap	Lease Cost LeaseCost	-15000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2524000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2796000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	670000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	551000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2306000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2568000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	2976000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3119000	usd
CY2022Q2	crdf	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	137000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3499000	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y8M12D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y2M12D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.070
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.070
CY2022Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	180000	usd
CY2021Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	243000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	251000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	483000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	300000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	737000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	754000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	775000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	796000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	523000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	2976000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1055000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1036000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2207000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1304000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	3000000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1200000	usd
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	3150000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	5150000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	3150000	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4490159	shares
CY2021Q4	crdf	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	5.80
CY2022Q1	crdf	Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights	P3Y
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4490159	shares
CY2022Q2	crdf	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	5.80
	crdf	Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights	P2Y6M

Files In Submission

Name	View Source	Status
0001628280-22-021044-index-headers.html	Edgar Link	pending
0001628280-22-021044-index.html	Edgar Link	pending
0001628280-22-021044.txt	Edgar Link	pending
0001628280-22-021044-xbrl.zip	Edgar Link	pending
crdf-063022exhibit311.htm	Edgar Link	pending
crdf-063022exhibit312.htm	Edgar Link	pending
crdf-063022exhibit321.htm	Edgar Link	pending
crdf-063022exhibit322.htm	Edgar Link	pending
crdf-20220630.htm	Edgar Link	pending
crdf-20220630.xsd	Edgar Link	pending
crdf-20220630_cal.xml	Edgar Link	unprocessable
crdf-20220630_def.xml	Edgar Link	unprocessable
crdf-20220630_htm.xml	Edgar Link	completed
crdf-20220630_lab.xml	Edgar Link	unprocessable
crdf-20220630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRDF
Cardiff Oncology, Inc. Stock $crdf

2022 Q3 Form 10-Q Financial Statement

#000162828022021044 Filed on August 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF Cardiff Oncology, Inc. Stock $crdf

2022 Q3 Form 10-Q Financial Statement

#000162828022021044 Filed on August 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF
Cardiff Oncology, Inc. Stock $crdf